{"entity":{"id":"idea-tcr-t-beyond-hla-a2","kind":"idea","name":"Extending sarcoma TCR-T beyond HLA-A*02","aka":[],"tldr":"Today's engineered T-cell therapies for sarcoma only work in the ~40-50% of people with one particular HLA type; new receptors for other HLA types would open them to everyone.","summary":"Afamitresgene autoleucel and letetresgene autoleucel, the engineered T-cell receptor therapies for synovial sarcoma, work only in people whose HLA type is A*02:01, A*02:05 or A*02:06, which excludes around half of patients. This idea would open TCR-T to everyone by discovering receptors that recognise the same antigens, MAGE-A4 and NY-ESO-1, presented by other alleles such as HLA-A*24, HLA-B*35 and HLA-C*07. The rationale is that antigen expression is independent of HLA type, so the barrier is a receptor discovery problem, and platforms at Immatics, T-knife and Adaptimmune have already isolated candidate receptors. The proposed test is a basket phase 1/2 across HLA types; the evidence is preclinical, and the idea addresses the bottleneck of rare and paediatric cancers without markets.","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT03967223: IGNYTE-ESO","url":"https://clinicaltrials.gov/study/NCT03967223"}],"tags":[],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":["tcr-t"],"targets":["mage-a4"],"drugs":["afamitresgene-autoleucel","letetresgene-autoleucel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-spearhead-1-lancet-2024"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"MAGE-A4- or NY-ESO-1-directed TCR-T restricted to HLA-A*24:02 or HLA-B*35 achieves response rates comparable to afami-cel in synovial sarcoma.","rationale":"Antigen expression is HLA-independent; the binding problem is solved by receptor discovery, not biology.","test":"Basket phase 1/2 across HLA types with shared antigen; pooled ORR endpoint.","maturity":"preclinical-evidence"},"route":"/ideas/idea-tcr-t-beyond-hla-a2/","neighbours":{"cancer":[{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"technology":[{"id":"tcr-t","kind":"technology","name":"TCR-T cell therapy","route":"/technologies/tcr-t/"}],"target":[{"id":"mage-a4","kind":"target","name":"MAGE-A4","route":"/targets/mage-a4/"}],"drug":[{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/"},{"id":"letetresgene-autoleucel","kind":"drug","name":"Letetresgene autoleucel","route":"/drugs/letetresgene-autoleucel/"}],"paper":[{"id":"paper-spearhead-1-lancet-2024","kind":"paper","name":"SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma","route":"/key-papers/paper-spearhead-1-lancet-2024/"}],"bottleneck":[{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/"}]}}